Philip Tagari ^Investor

Philip Tagari is a seasoned Chief Scientific Officer with a strong background in drug discovery and research. With over a decade of experience at Amgen Inc, he has successfully advanced numerous innovative molecules into clinical development and commercialization. Philip's expertise lies in redefining disease biology and implementing novel approaches to accelerate the delivery of therapeutics to patients. He is also actively involved in various organizations such as CQDM and BenchSci, showcasing his commitment to advancing the field of biology and drug discovery. His achievements include contributions to the discovery of Singulair® and Vioxx® during his time at Merck Frosst.